Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the ...

Please provide your email address to receive an email when new articles are posted on . Among patients with cardiogenic shock, there was no difference between the inotropic agents milrinone and ...

A head-to-head comparison of inotropes in the setting of cardiogenic shock revealed no clear victor, with milrinone and dobutamine providing similar outcomes in the randomized DOREMI trial. A ...

(UPDATED) A hastily convened collaboration between physicians, pharmacists, and industry experts has pulled together guidance for hospitals and clinicians navigating the US dobutamine shortage that ...

Risk stratification of patients after an acute myocardial infarction (AMI) is essential; however, using left ventricular ejection fraction as a prognostic marker can underestimate the functional ...

A head-to-head randomized comparison of milrinone and dobutamine — the most used inotropes in cardiogenic shock therapy in North America — failed to find a significant advantage for one agent over the ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. DBL Dobutamine Hydrochloride Injection contains the active ingredient ...